Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03750734
Other study ID # P02437
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 10, 2019
Est. completion date August 9, 2021

Study information

Verified date March 2022
Source Papworth Hospital NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Bronchiectasis is a long-term lung condition where the airways become abnormally enlarged, leading to a build-up of mucus and inflammation that makes the lungs more susceptible to recurrent infection. Patients with bronchiectasis have subtle abnormalities in the way their airway cells respond to infection that are, in part, responsible for the development of their condition. At present there are no licensed treatments for bronchiectasis. This study will aim to characterise in depth some of these abnormalities with a view to future studies that will try to develop treatments that can directly target those abnormalities at a molecular level. Patients known to have bronchiectasis who have provided written informed consent will be enrolled alongside healthy volunteers and patients with chronic obstructive pulmonary disease and cystic fibrosis, for comparison. Participants will give a blood sample and have a bronchoscopy. This is a thin telescopic tube, passed through the nose or mouth, under sedation, into the airways that will allow a sample of bronchial epithelial cells to be taken. The main objective of the study is to achieve a greater understanding of some of the key biological processes/pathways and disease marker genes that play a role in the development of bronchiectasis. This is important because, at present, little is known about the underlying disease mechanisms and there are no licensed treatments for bronchiectasis. The investigator's hope this in-depth characterisation of specific bronchial epithelial cell abnormalities in bronchiectasis will shed light on novel targets for future drug discovery.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date August 9, 2021
Est. primary completion date August 9, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Bronchiectasis participants 1. Confirmed HRCT diagnosis of bronchiectasis in more than 1 lobe 2. Bronchiectasis not attributable to another cause, e.g. cystic fibrosis/ABPA/PCD 3. Absence of significant emphysema, COPD or asthma 4. Have provided written informed consent that they are willing to participate in the study prior to sample collection COPD participants (disease controls) 1. Confirmed diagnosis of COPD according to GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria (FEV1/FVC ratio < 0.70) 2. Absence of significant bronchiectasis on HRCT 3. Have provided written informed consent that they are willing to participate in the study prior to sample collection Cystic fibrosis participants (disease controls) 1. Have a confirmed diagnosis of cystic fibrosis 2. Have provided written informed consent that they are willing to participate in the study prior to sample collection Healthy controls 1. No history or diagnosis of clinically significant lung disease 2. Be a non-smoker for > 1 year at screening and have < 5 pack year history of smoking 3. Have provided written informed consent that they are willing to participate in the study prior to sample collection Exclusion Criteria: 1. Any clinically significant acute illness, including recent exacerbation of lung disease requiring treatment with oral or intravenous antibiotics, in 6 weeks prior to screening 2. Any contraindication to safe bronchoscopy as judged by CI or clinical team (FEV1 < 30% predicted, oxygen saturations < 92% on room air etc.) 3. Any clinically significant bleeding disorder or use of anticoagulant/antiplatelet therapy that could place participants at risk of bleeding 4. Any contraindication to sedation or local anaesthetic medications used for bronchoscopy 5. Current smoking within 6 months prior to screening (defined as someone who has smoked at least one cigarette per day (or pipe, cigar, or cannabis) for = 30 days within 6 months prior to screening) 6. Acute MI, acute stroke or major surgery within 6 months prior to screening 7. History of uncontrolled ischaemic heart disease that place participants at risk during bronchoscopy 8. History of ventilatory failure or hypercapnia that may complicate bronchoscopy 9. Any known active tuberculous or non-tuberculous mycobacterial infection 10. Any use of oral corticosteroids within 4 weeks of screening 11. Any systemic immunomodulatory or immunosuppressive therapy within 3 months of screening 12. Known current malignancy or current evaluation for a potential malignancy 13. Any other clinically significant medical disease that is uncontrolled despite treatment, that is likely, in the opinion of the investigators, to impact the patient's ability to safely participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Bronchoscopy
Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
Blood test
Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.

Locations

Country Name City State
United Kingdom Royal Papworth Hospital Cambridge

Sponsors (2)

Lead Sponsor Collaborator
Papworth Hospital NHS Foundation Trust GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identification and comparison of molecular pathways, including through gene expression analysis of airway tissues. Identification and comparison of molecular pathways, including through gene expression analysis of airway tissues. 2 years
Secondary Generation of air liquid interface cultures from primary bronchial epithelial cells/IPSC derived bronchial epithelial cells Generation of air liquid interface cultures from primary bronchial epithelial cells/IPSC derived bronchial epithelial cells 2 years
Secondary Functional characterisation of airway epithelium Functional characterisation of airway epithelium 2 years
See also
  Status Clinical Trial Phase
Completed NCT05034900 - Does Addition of Oscillatory Positive Expiratory Pressure (OPEP) Device to a Chest Physiotherapy Program Provide Further Health Benefits in Children With Bronchiectasis? N/A
Recruiting NCT04101448 - Prevalence of Bronchiectasis in COPD Patients
Withdrawn NCT03376204 - Pain Mechanisms in Patients With Bronchiectasis
Completed NCT02550821 - Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects
Completed NCT02656992 - Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis N/A
Completed NCT02282202 - Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD N/A
Completed NCT02048397 - Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Recruiting NCT01761214 - Bacteriology and Inflammation in Bronchiectasis N/A
Recruiting NCT02527486 - Seoul National University Airway Registry N/A
Completed NCT01578681 - ELTGOL and Bronchiectasis. Respiratory Therapy N/A
Completed NCT01854788 - 3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis N/A
Completed NCT00769119 - A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis Phase 2
Completed NCT01117493 - Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis N/A
Terminated NCT00524095 - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis Phase 2
Recruiting NCT00129350 - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Phase 1
Completed NCT00656721 - Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients N/A
Completed NCT04081740 - Biological Determinants of Sputum Rheology in Chronic Airway Diseases
Enrolling by invitation NCT02546297 - Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis Phase 4
Completed NCT03628456 - Effect of HFCWO Vests on Spirometry Measurements N/A